| Literature DB >> 25157968 |
Laura E MacConaill1, Elizabeth Garcia2, Priyanka Shivdasani2, Matthew Ducar3, Ravali Adusumilli3, Marc Breneiser3, Mark Byrne2, Lawrence Chung2, Jodie Conneely2, Lauren Crosby2, Levi A Garraway4, Xin Gong2, William C Hahn4, Charlie Hatton3, Philip W Kantoff5, Michael Kluk2, Frank Kuo2, Yonghui Jia2, Ruchi Joshi2, Janina Longtine2, Allison Manning2, Emanuele Palescandolo3, Nematullah Sharaf2, Lynette Sholl2, Paul van Hummelen3, Jacqueline Wade2, Bruce M Wollinson3, Dimity Zepf2, Barrett J Rollins5, Neal I Lindeman6.
Abstract
Ongoing cancer genome characterization studies continue to elucidate the spectrum of genomic abnormalities that drive many cancers, and in the clinical arena assessment of the driver genetic alterations in patients is playing an increasingly important diagnostic and/or prognostic role for many cancer types. However, the landscape of genomic abnormalities is still unknown for less common cancers, and the influence of specific genotypes on clinical behavior is often still unclear. To address some of these deficiencies, we developed Profile, a prospective cohort study to obtain genomic information on all patients at a large tertiary care medical center for cancer-related care. We enrolled patients with any cancer diagnosis, and, for each patient (unselected for cancer site or type) we applied mass spectrometric genotyping (OncoMap) of 471 common recurrent mutations in 41 cancer-related genes. We report the results of the first 5000 patients, of which 26% exhibited potentially actionable somatic mutations. These observations indicate the utility of genotyping in advancing the field of precision oncology.Entities:
Mesh：
Year: 2014 PMID： 25157968 PMCID： PMC4210463 DOI： 10.1016/j.jmoldx.2014.06.004
Source DB: PubMed Journal: J Mol Diagn ISSN： 1525-1578 Impact factor: 5.568